Investigator-Initiated Study of Jacobio’s JAB-3312 in Combination with VIT in Malignant Peripheral Nerve Sheath Tumors Conducted in the United States

2026

Investigator-Initiated Study of Jacobio’s JAB-3312 in Combination with VIT in Malignant Peripheral Nerve Sheath Tumors Conducted in the United States

Oct 29, 2026

BEIJING, China, Oct. 29, 2026 — Jacobio Pharma (1167.HK) today announced that an investigator-initiated Phase 1b/2 clinical study of JAB-3312 in combination with vincristine, irinotecan, and temozolomide (VIT) is being conducted in the United States in patients with relapsed or refractory malignant peripheral nerve sheath tumors (MPNST).

The study will evaluate the safety, tolerability, and preliminary antitumor activity of JAB-3312 in combination with VIT in patients with relapsed or refractory MPNST, exploring the therapeutic potential of this combination.

JAB-3312 is an allosteric SHP2 inhibitor independently developed by Jacobio. This study will further explore its potential in combination therapy and a new indication. Meanwhile, a Phase 3 trial of JAB-3312 in combination with glecirasib as a first-line treatment for patients with KRAS G12C-mutated non-small cell lung cancer is ongoing in China.

About Jacobio

Jacobio Pharma (1167.HK) is committed to providing breakthrough treatments for patients. With an induced allosteric drug discovery platform, the company’s core projects focus on the KRAS pathway. The company envisions becoming a global leader in research and development, fostering strategic partnerships to drive innovation. Jacobio’s R&D centers are located in Beijing, Shanghai (China), and Boston (USA). Clinical trials are conducted at over 180 sites in China, more than 30 sites in the USA, and over 10 sites across several European countries.
For more information, please visit: http://www.jacobiopharma.com